Clinical trials: Multifocal Breast Carcinoma
Estrogen Receptor Positive, HER2/Neu Negative
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
This phase I/II trial studies side effects and best dose of copanlisib when given together with letrozole and palbociclib and to see how well they work in treating hormone receptor positive HER2 negative stage I-IV breast cancer.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT03128619
- Testing
- Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Diffusion-Weighted MRI for Diagnosis of Multifocal, Multicentric Breast Cancer
Detection of multifocal, multicentric breast cancer in patients with breast cancer affects surgical decision. Histology-proven additional cancer foci have been reported to be detected in 21.0% to 63.0% of affected breasts in…
- Trial name
- NCT04656639
- Where
- South Korea
- Volunteers
- 580 people
- Sponsor
- Seoul National University Hospital
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive [HR+]) and HER2…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04481113
- Testing
- Abemaciclib, Niraparib Tosylate Monohydrate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Survival of BCS vs Mx in Asymptomatic Screen-detected NPBC
We performed this study on a consecutive cohort of women with asymptomatic screen-detected NPBC. The clinicopathological characteristics, 10-year relapse-free survival (RFS) and overall survival (OS) were compared between BCS and…
- Trial name
- NCT06103032
- Testing
- Breast Conserving Surgery, Mastectomy
- Where
- China
- Volunteers
- 1,020 people
- Sponsor
- Peking Union Medical College Hospital
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
This phase III trial compares the effect of usual treatment with trastuzumab emtansine (T-DM1) alone vs. T-DM1 in combination with tucatinib.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT04457596
- Testing
- Trastuzumab Emtansine, Tucatinib, Questionnaire Administration
- Where
- 1,176 sites in United States, Canada and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in…
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT01272037
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- 1,568 sites in United States, Canada and 8 more
- Volunteers
- 5,018 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging
In order to explain the value of adding CESM into the clinical pathway, and also to obtain the relevant clinical data to support future update of clinical guideline, we plan to evaluate the detection rate of CESM for additional…
- Trial name
- COMBO-I (NCT06475066)
- Testing
- contrast-enhanced spectral mammography
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Breast Cancer
Safety of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer
The objective of this observational study is to evaluate the oncological safety of breast-conserving surgery combined with standard postoperative radiotherapy in adult female patients diagnosed with multifocal or multicentric…
- Trial name
- NCT07677956
- Testing
- Breast-conserving surgery, postoperative radiotherapy and individualized adjuvant systemic therapy
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)
Lay Summary After patients are diagnosed with breast cancer, they undergo breast magnetic resonance (MR) imaging to determine if the cancer is located in more than one place in the breast.
- Trial name
- NCT00957099
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Breast Cancer
Evaluating New Surgical Technique in Management of Female Patients With Operable Multifocal Breast Cancer
Multi-focal Breast Cancers(MFBC) still have undiscoverable Clinical Significance reflecting on a debatable surgical decision for this Category of breast cancer.
- Trial name
- NCT03900299
- Testing
- oncoplastic breast surgery
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Alexandria University
Breast Cancer
Sentinel Lymph Node Technique in Multifocal Breast Cancer
The scope of this trial is to assess the Sentinel Lymph Node Technique in Multifocal Breast Cancer
- Trial name
- IGASSU (NCT00417495)
- Testing
- Sentinel Lymph Node Technique
- Where
- 20 sites in France
- Volunteers
- 216 people
- Sponsor
- Centre Oscar Lambret